|
LDA NEWS & UPDATES
November 30, 2022
| |
|
When the Lyme Disease Association Inc. (LDA) was contacted by a student at Duke Law who wanted to organize a group of students in a Lyme disease pro bono project, I was very excited about the possibilities. As a former teacher, parent-teacher organization president, and board of education president, I had always been involved in spreading knowledge, providing input into what that knowledge should consist of, and overseeing its delivery.
Later, when my life took an unexpected turn - Lyme disease devastating my area and family - I discerned I still had the same goals, but a different topic in different venues. My focus was now on a disease topic that I initially knew nothing about, nor did most professionals. I really did not want to know about Lyme, but it was a huge problem few wanted to tackle. I intimately saw the devastation it produced in the school district and in families, my own and my friends’. Read more.
| |
| |
|
Daniel J.B. Clarke, et al, published “Gene set predictor for post-treatment Lyme disease” in Cell Reports Medicine on November 15, 2022. The researchers enrolled 152 study participants, each with symptoms of post-treatment Lyme disease (PTLD), to analyze their peripheral blood mononuclear cells (PBMCs) with RNA sequencing (RNA-seq). RNA-seq data from 72 individuals with acute Lyme disease and 44 uninfected controls were incorporated to examine variations in differential gene expression. Read more. | |
|
B. burgdorferi, Dave Dorward, P.hD., NIH
Read the study.
| |
Timothy C. Saylor, et al., published “Borrelia burgdorferi, the Lyme disease spirochete, possesses genetically-encoded responses to doxycycline, but not to amoxicillin” in PLOS ONE on September 30, 2022. The study examines whether B. burgdorferi responds to antibiotic stresses by creating proteins that provide a safeguard against antibiotics, and therefore changing its transcription profile, as some species of bacteria have been found to do. Read more. | |
|
As reported on WDRB.com on November 9, 2022, from Tarsus Pharmaceuticals, Inc. (GLOBAL NEWSWIRE) Tarsus “is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1b clinical trial.”
According to Tarsus' website, TP-05 is “the only non-vaccine drug-based preventive therapeutic in development that targets and kills infected tick vectors before they can kill Borrelia burgdorferi….” Read more.
| |
|
Deer Tick Questing
Credit: James Occi, Ph.D.
| |
Shannon Baron, et al., published, “Unresolved Heart Block in Lyme Carditis: A Case Report” in Cureus on September 27, 2022, chronicling the case of a man who was admitted to the emergency department with a day-long history of syncopal episodes. Read more. | |
| |
|
Samudyata, et al., published the study “SARS-CoV-2 promotes microglial synapse elimination in human brain organoids” in Molecular Psychiatry on October 5, 2022, to better understand what COVID-19 can do to the human brain. Neuropsychiatric symptoms occur often in both the acute and post-acute stages of SARS-CoV-2 infections, however, the mechanisms of these manifestations have remained unknown. Read more. | |
Business Insurance published an article on November 2, 2022, noting parallels between long-term issues caused by Lyme disease and COVID-19 infections. Medical experts believe much can be learned from a disease that results from the bite of an infected tick. Read more. | |
|
Skyler M. Kerr, et al., published “Statewide survey of medically important ticks on white-tailed deer, Odocoileus virginianus Zimmerman, in Alabama, U.S.A.” on October 18, 2022, in Journal of Vector Ecology. The researchers assessed tick fauna found on deer located in Alabama from a state-wide study taking place during hunting seasons 2019-2020 and 2020-2021. Read more. | |
| |
|
According to a Montreal Gazette article, an announcement was made by the CIUSSS West-Central Montreal regional health authority, on October 31, 2022, that a clinic for patients with persistent COVID-19 and Lyme disease symptoms has opened at the Jewish General Hospital in Montreal, Quebec, Canada. Earlier this year, Quebec announced plans to open 15 clinics that will specialize in long COVID and Lyme disease, as well as five referral centers and 10 satellite clinics. Read more. | |
Olivia Goodreau, Founder of the LivLyme Foundation, launched a newly created app that tracks long-haul disease symptoms called the LonghaulTracker on November 17, 2022. This is the second app created by the eighteen-year-old and was developed for the millions of individuals living with long-haul or chronic diseases. The LonghaulTracker makes it possible for users to record and track their symptoms over time as well as download a report for caregivers and medical providers. Read more. | |
| |
|
In response to the Biden administration’s issuance of the Presidential Memorandum on Addressing the Long-Term Effects of COVID-19, the U.S. Department of Health and Human Services (HHS) published “Health+ Long COVID Human-Centered Design Report” in October 2022 which expands on two prior publications released in August 2022– “Services and Supports for Longer-Term Impacts of COVID-19” and “National Research Action Plan on Long COVID.” Read more. | |
Katherine Leavey, et al., published, “Lyme borreliosis in pregnancy and associations with parent and offspring health outcomes: An international cross-sectional survey” in Frontiers in Medicine on November 3, 2022. Data regarding the health outcomes of people infected with Lyme disease during pregnancy is limited, as is perinatal transmission to their fetus, and the long-term effects on their children. This study investigated the impact of Lyme disease in pregnancy on both the parent and their offspring. Read more. | |
|
Arick P. Sabin, et al., published “Clinical evaluation of a Borrelia modified two-tiered testing (MTTT) shows increased early sensitivity for Borrelia burgdorferi but not other endemic Borrelia species in a high incidence region for Lyme disease in Wisconsin” in Diagnostic Microbiology and Infectious Disease on November 9, 2022,* (version of record). Recently, a modified two-tiered testing algorithm (MTTT; ZEUS Scientific) for B. burgdorferi was cleared by the FDA. This led the researchers to assess the algorithm to verify Lyme disease as well as evaluate the results compared to those acquired using standard two-tiered testing (STTT). Read more. | |
| |
|
Michael Lum, et al., published “Procalcitonin as a Potential Biomarker in the Study of Babesiosis Caused by B. microti” in Pathogens on October 23, 2022. Thirty-three acute babesiosis cases from 2012 through 2019 were collected retroactively from Long Island-based Stony Brook University Hospital (SBUH) and Stony Brook South Hampton Hospital (SHH). The cases were cross-referenced for necessary ICU admission, and procalcitonin levels were measured using BRAHMS Elecsys assay at SBUH and BRAHMS Architect assay at SHH. Read more. | |
I. Scapularis, credit: James Occi, Ph.D., LDA Scientific & Professional Advisory Board | |
Eric L. Siegel, et al., published “Spatial repellents transfluthrin and metofluthrin affect the behavior of Dermacentor variabilis, Amblyomma americanum, and Ixodes scapularis in an in vitro vertical climb assay” in PLOS ONE | |
|
on November 8, 2022. The study assessed the efficacy of the repellents against adult, female ticks of the three species via an in vitro vertical climb assay. Read more.
Read the study.
| |
Rappahannock News published “Lyme disease is on the rise in Rappahannock. The pandemic obscured by how much” by Ike Parrish for Foothills Forum on November 20, 2022. Over the past five years, Daniel Ferrel, Epidemiologist for the Rappahannock-Rapidan Health District, has seen a rise in Lyme disease, Rocky Mountain spotted fever, Anaplasmosis, and Ehrlichiosis cases in his district which covers Rappahannock, Culpeper, Fauquier, Madison and Orange Counties. Other experts and local residents also believe tick-borne disease cases have been vastly under-reported throughout the state. Read more. | |
| |
|
Independent film distribution company, First Run Features, has acquired U.S. rights to The Quiet Epidemic, a documentary film about Chronic Lyme and other tick-borne diseases. Read more. | |
The U.S. Department of Health and Human Services (HHS) and the Steven & Alexandra Cohen Foundation (Cohen Foundation) have named ten Phase 1 LymeX Diagnostics Prize winners in the LymeX Innovation Accelerator (LymeX) contest created to advance the progress of diagnostics for Lyme disease. Read more. | |
| |
|
You may choose where your donation goes. Donate in Honor or Memory of a loved one, or send a Happy Holiday or Holiday Memorial donation. There are a variety of others to choose from (birthday, wedding, anniversary or Lyme awareness). You can have a notification letter emailed or postal mailed with a personalized note. This makes a thoughtful gift for those special people on your holiday list who have been impacted by Lyme or who are concerned about the spread of Lyme and tick-borne diseases. Visit donation page. | |
|
The Lyme Disease Association Inc. (LDA) does not charge any membership fees. Most of our
materials are free to download and most of our videos are free on YouTube. Our nationwide
doctor referral system is free to access. Printed brochures can be ordered for S&H only.
| |
888-366-6611 Toll Free Info Line
| | | | | |
